Evidence map›Paper›PMID 31683613›Full record

ArticleInternational journal of molecular sciences2019

RETRACTED: Neutral Sphingomyelinase Modulation in the Protective/Preventive Role of rMnSOD from Radiation-Induced Damage in the Brain.

Samuela Cataldi, Antonella Borrelli, Maria Rachele Ceccarini, Irina Nakashidze, Michela Codini, Oleg Belov, Alexander Ivanov, Eugene Krasavin, Ivana Ferri, Carmela Conte and 7 more

RetractedOpen access · goldAbstract readRetracted Publication
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Samuela CataldiDepartment of Pharmaceutical Sciences, University of Perugia, 06126 Perugia, Italy. samuelacataldi@libero.it.ORCID 0000-0002-0588-1658
Antonella BorrelliMolecular Biology and Viral Oncology Unit, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", 80131 Napoli, Italy. a.borrelli@istitutotumori.na.it.ORCID 0000-0002-4439-6882
Maria Rachele CeccariniDepartment of Pharmaceutical Sciences, University of Perugia, 06126 Perugia, Italy. chele@hotmail.it.
Irina NakashidzeDepartment of Pharmaceutical Sciences, University of Perugia, 06126 Perugia, Italy. irinanakashidze@yahoo.com.ORCID 0000-0001-8934-6312
Michela CodiniDepartment of Pharmaceutical Sciences, University of Perugia, 06126 Perugia, Italy. michela.codini@unipg.it.ORCID 0000-0002-1562-4495
Oleg BelovLaboratory of Radiation Biology, Joint Institute for Nuclear Research, 141980 Dubna, Russia. dem@jinr.ru.
Alexander IvanovLaboratory of Radiation Biology, Joint Institute for Nuclear Research, 141980 Dubna, Russia. a1931192@mail.ru.
Eugene KrasavinLaboratory of Radiation Biology, Joint Institute for Nuclear Research, 141980 Dubna, Russia. krasavin@jinr.ru.
Ivana FerriDivision of Pathological Anatomy and Histology, Department of Experimental Medicine, School of Medicine and Surgery, University of Perugia, 06126 Perugia, Italy. ivanaferri@gmail.com.
Carmela ConteDepartment of Pharmaceutical Sciences, University of Perugia, 06126 Perugia, Italy. carmela.conte@unipg.it.ORCID 0000-0003-2456-6300
Federica Filomena PatriaDepartment of Pharmaceutical Sciences, University of Perugia, 06126 Perugia, Italy. patriafederica@gmail.com.ORCID 0000-0001-9010-4150
Giovanna TrainaDepartment of Pharmaceutical Sciences, University of Perugia, 06126 Perugia, Italy. giovanna.traina@unipg.it.
Tommaso BeccariDepartment of Pharmaceutical Sciences, University of Perugia, 06126 Perugia, Italy. tommaso.beccari@unipg.it.ORCID 0000-0001-9637-6579
Aldo ManciniLaedhexa Biotechnologies Inc., San Francisco, CA QB3@953, USA. aldo_mancini@tiscali.it.
Francesco CurcioDipartimento di Area Medica, University of Udine, 33100 Udine, Italy. francesco.curcio@uniud.it.ORCID 0000-0002-9070-4807
Francesco Saverio Ambesi-ImpiombatoDipartimento di Area Medica, University of Udine, 33100 Udine, Italy. ambesis@me.com.
Elisabetta AlbiDepartment of Pharmaceutical Sciences, University of Perugia, 06126 Perugia, Italy. elisabetta.albi@unipg.it.ORCID 0000-0002-5745-5343
University of Perugia · ITJoint Institute for Nuclear Research · RUUniversity of Udine · ITIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale" · IT

Funding

Italian Space Agency "Project RASC 2015-008-R.0
6 · The paper itself

Abstract

Studies on the relationship between reactive oxygen species (ROS)/manganese superoxide dismutase (MnSOD) and sphingomyelinase (SMase) are controversial. It has been demonstrated that SMase increases the intracellular ROS level and induces gene expression for MnSOD protein. On the other hand, some authors showed that ROS modulate the activation of SMase. The human recombinant manganese superoxide dismutase (rMnSOD) exerting a radioprotective effect on normal cells, qualifies as a possible pharmaceutical tool to prevent and/or cure damages derived from accidental exposure to ionizing radiation. This study aimed to identify neutral SMase (nSMase) as novel molecule connecting rMnSOD to its radiation protective effects. We used a new, and to this date, unique, experimental model to assess the effect of both radiation and rMnSOD in the brain of mice, within a collaborative project among Italian research groups and the Joint Institute for Nuclear Research, Dubna (Russia). Mice were exposed to a set of minor γ radiation and neutrons and a spectrum of neutrons, simulating the radiation levels to which cosmonauts will be exposed during deep-space, long-term missions. Groups of mice were treated or not-treated (controls) with daily subcutaneous injections of rMnSOD during a period of 10 days. An additional group of mice was also pretreated with rMnSOD for three days before irradiation, as a model for preventive measures. We demonstrate that rMnSOD significantly protects the midbrain cells from radiation-induced damage, inducing a strong upregulation of nSMase gene and protein expression. Pretreatment with rMnSOD before irradiation protects the brain with a value of very high nSMase activity, indicating that high levels of activity might be sufficient to exert the rMnSOD preventive role. In conclusion, the protective effect of rMnSOD from radiation-induced brain damage may require nSMase enzyme.

Indexed as

AnimalsBrainFemaleGene ExpressionMice, Inbred ICRRadiation, IonizingRadiation-Protective AgentsReactive Oxygen SpeciesRecombinant ProteinsSphingomyelin PhosphodiesteraseSuperoxide DismutaseRadiation-Protective AgentsReactive Oxygen SpeciesRecombinant ProteinsSphingomyelin PhosphodiesteraseSuperoxide Dismutasebraincell signalingneutral sphingomyelinasepathologyradiationsphingomyelin metabolism

Identifiers

PMID31683613
PMCPMC6862120
OpenAlexW2982439616

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.